longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

HITECK

300683

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

About

HITECK
HITECK
300683.SZ

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the production and sales of bioengineering products and lyophilized powder injections in China and internationally. The company operates through Biopharmaceutical Division; Pharmaceutical Technology Services Division; In Vitro Diagnostic Reagents Division; Production and Sales Division of Active Pharmaceutical Ingredients and Pharmaceutical Intermediates; and Other Divisions segments. Its products include Epramine for injection; mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis; tinidazole suppository, acyclovir dispersible tablets, nimodipine extended-release tablets, trimetazidine hydrochloride tablets, azithromycin granules, esomeprazole sodium for injection, and cyclic adenosine monophosphate for injection; Pentoxone theobromine injection; Roxatidine Acetate Hydrochloride for Injection; and Terizazole phosphate for injection. The company also provides measles and rubella virus nucleic acid detection kits; isolation and identification tubes and kits for mycoplasma; and bacterial vaginosis (BV) rapid test kits, as well as diagnostic kits for novel coronavirus N-Protein, as well as raw materials and intermediates.

Profile

Company Name
Wuhan Hiteck Biological Pharma Co.,Ltd
Market
SZSE
Founded
1992-04-08
Industry
--
Fiscal Year End
December 31
Website
www.hiteck.com.cn